EA200001221A1 - Новая форма ирбесартана, способы получения указанной формы и содержащие ее фармацевтические композиции - Google Patents

Новая форма ирбесартана, способы получения указанной формы и содержащие ее фармацевтические композиции

Info

Publication number
EA200001221A1
EA200001221A1 EA200001221A EA200001221A EA200001221A1 EA 200001221 A1 EA200001221 A1 EA 200001221A1 EA 200001221 A EA200001221 A EA 200001221A EA 200001221 A EA200001221 A EA 200001221A EA 200001221 A1 EA200001221 A1 EA 200001221A1
Authority
EA
Eurasian Patent Office
Prior art keywords
irbesartan
habit
obtaining
methods
pharmaceutical compositions
Prior art date
Application number
EA200001221A
Other languages
English (en)
Other versions
EA003410B1 (ru
Inventor
Брюно Франк
Кристиан Офф
Сэн Кайэнг
Марк Д. Линдрад
Оливье Моннье
Ченкоу Уэй
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9527829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200001221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of EA200001221A1 publication Critical patent/EA200001221A1/ru
Publication of EA003410B1 publication Critical patent/EA003410B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение касается формы А ирбесартана, имеющей такой измененный габитус кристаллов, что соотношение длина/ширина находится в пределах от 1:1 до 10:1, предпочтительно от 1:1 до 5:1, и способа получения указанного габитуса кристаллов. Способ отличается тем, что либо подвергают суспензию кристаллов формы А ирбесартана, имеющую игольчатый габитус, по меньшей мере, одной стадии температурного колебания, либо подвергают суспензию кристаллов формы А ирбесартана, имеющую игольчатый габитус, механической резке. Данное изобретение также относится к фармацевтической композиции, содержащей ирбесартан указанного кристаллического габитуса.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001221A 1998-06-24 1999-06-10 Новая форма ирбесартана, способы получения указанной формы и содержащие ее фармацевтические композиции EA003410B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808037A FR2780403B3 (fr) 1998-06-24 1998-06-24 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
PCT/FR1999/001372 WO1999067236A1 (fr) 1998-06-24 1999-06-10 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant

Publications (2)

Publication Number Publication Date
EA200001221A1 true EA200001221A1 (ru) 2001-08-27
EA003410B1 EA003410B1 (ru) 2003-04-24

Family

ID=9527829

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001221A EA003410B1 (ru) 1998-06-24 1999-06-10 Новая форма ирбесартана, способы получения указанной формы и содержащие ее фармацевтические композиции

Country Status (25)

Country Link
US (2) US6800761B1 (ru)
EP (1) EP1089994B9 (ru)
JP (1) JP2002518495A (ru)
KR (1) KR20010034917A (ru)
CN (1) CN1127499C (ru)
AT (1) ATE275562T1 (ru)
AU (1) AU747887B2 (ru)
BG (1) BG105069A (ru)
BR (1) BR9912198A (ru)
CA (1) CA2335545A1 (ru)
CZ (1) CZ292868B6 (ru)
DE (1) DE69920017T2 (ru)
EA (1) EA003410B1 (ru)
FR (1) FR2780403B3 (ru)
HU (1) HUP0103913A3 (ru)
ID (1) ID27377A (ru)
IL (1) IL140419A0 (ru)
NO (1) NO317786B1 (ru)
NZ (1) NZ508842A (ru)
PL (1) PL345215A1 (ru)
SK (1) SK20032000A3 (ru)
TR (1) TR200003842T2 (ru)
UA (1) UA55540C2 (ru)
WO (1) WO1999067236A1 (ru)
ZA (1) ZA200007588B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176793A1 (en) * 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
EP2189457A1 (en) 2003-01-16 2010-05-26 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
AU2007202693B2 (en) * 2003-01-20 2009-12-10 Novartis Ag Process for modifying drug crystal formation
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
US7038060B2 (en) * 2003-02-05 2006-05-02 Teva Pharmaceutical Industries Ltd. Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one
AU2004268983A1 (en) * 2003-08-27 2005-03-10 Boehringer Ingelheim International Gmbh Cycloalkylaminoacid compounds, processes for making and uses thereof
US20090286990A1 (en) * 2004-05-20 2009-11-19 Reguri Buchi Reddy Process for preparing irbesartan
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
SI21848A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata
TWI346108B (en) * 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
WO2006050923A1 (en) * 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Polymorph form of irbesartan
EP1806130B1 (en) * 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
UA96476C2 (ru) * 2007-04-17 2011-11-10 Ратиофарм Гмбх Фармацевтические композиции, которые содержат ирбесартан
CN101801371B (zh) * 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
ES2349317T3 (es) 2007-11-28 2010-12-29 Laboratorios Lesvi, S.L. Formulaciones farmacéuticas que contienen irbesartán.
EP2215083A2 (en) * 2007-12-07 2010-08-11 Hetero Drugs Limited Process for pure irbesartan
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CZ302407B6 (cs) * 2009-03-12 2011-05-04 Univerzita Pardubice Zpusob prípravy 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-onu
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) * 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
PL2488515T3 (pl) * 2009-10-14 2017-07-31 Janssen Pharmaceutica Nv Sposób wytwarzania związków użytecznych jako inhibitory sglt2
MY187718A (en) 2010-05-11 2021-10-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
WO2012140120A1 (en) 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
HUE049895T2 (hu) * 2015-12-21 2020-11-30 Janssen Pharmaceutica Nv Kristályosítási eljárás kanagliflozin hemihidrát kristályok elõállítására

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
EP1089994B1 (fr) 2004-09-08
ID27377A (id) 2001-04-05
NO317786B1 (no) 2004-12-13
WO1999067236A1 (fr) 1999-12-29
ATE275562T1 (de) 2004-09-15
EP1089994B9 (fr) 2008-08-27
IL140419A0 (en) 2002-02-10
US7008959B2 (en) 2006-03-07
KR20010034917A (ko) 2001-04-25
EP1089994A1 (fr) 2001-04-11
HUP0103913A2 (hu) 2002-03-28
DE69920017T2 (de) 2005-09-22
SK20032000A3 (sk) 2001-05-10
FR2780403A1 (fr) 1999-12-31
ZA200007588B (en) 2001-06-11
CZ292868B6 (cs) 2003-12-17
UA55540C2 (ru) 2003-04-15
NO20006645D0 (no) 2000-12-22
TR200003842T2 (tr) 2001-06-21
FR2780403B3 (fr) 2000-07-21
CN1127499C (zh) 2003-11-12
DE69920017D1 (de) 2004-10-14
CZ20004771A3 (en) 2001-06-13
US6800761B1 (en) 2004-10-05
CN1306529A (zh) 2001-08-01
PL345215A1 (en) 2001-12-03
HUP0103913A3 (en) 2003-01-28
CA2335545A1 (en) 1999-12-29
AU4048499A (en) 2000-01-10
EA003410B1 (ru) 2003-04-24
NO20006645L (no) 2001-02-26
AU747887B2 (en) 2002-05-30
BG105069A (en) 2001-11-30
US20050032862A1 (en) 2005-02-10
JP2002518495A (ja) 2002-06-25
NZ508842A (en) 2002-09-27
BR9912198A (pt) 2001-04-10

Similar Documents

Publication Publication Date Title
EA200001221A1 (ru) Новая форма ирбесартана, способы получения указанной формы и содержащие ее фармацевтические композиции
EA200000819A1 (ru) Остеоимплантат и способ его изготовления
EA200000765A1 (ru) Получение липидной смеси и фосфолипидная суспензия, содержащая липидную смесь
RU94024563A (ru) Арилзамещенные гетероциклы, способ их получения, фармацевтическая композиция на их основе
PT96857A (pt) Processo para a preparacao de oxetanonas
DE69329247T2 (de) Kristallisierung von m-csf
BG95400A (bg) 1-арилимидазоли
EA200300462A1 (ru) Замещенные дипептиды в качестве средств, усиливающих секрецию гормона роста
ATE327250T1 (de) Kristallstruktur von ribosomen und proteinsynthese-inhibitoren
BR0212495A (pt) Método para a preparação de tetraidrobenzotiepinas cristalinas
ATE87308T1 (de) 3-aryluracile zur unkrautbekaempfung.
EA200501250A1 (ru) Композиция, содержащая смесь активных начал, и способ ее получения
DE60229267D1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
DE3887048D1 (de) Flüssigkristalline, insbesondere ferroelektrische flüssigkristalline Mischungen.
MA26767A1 (fr) Hydroxamates de sulfonamide
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
MA22932A1 (fr) Procede de preparation de compositions detergentes de densite apparente elevee et composition obtenue par ce procede.
RU2000101826A (ru) Кристаллические макролиды и способ их получения
BR8900834A (pt) 1,2,4-triazinodionas substituidas e processo para sua preparacao;compostos intermediarios para as mesmas e processos para sua preparacao;composicoes contra protozoarios parasitarios;processo para o combate dos mesmos;e processo para preparacao de composicoes contra protozoarios parasitarios
EA199800034A1 (ru) Способ получения n-монозамещенных и n,n'-дизамещенных асимметричных циклических мочевин
EA199900235A1 (ru) Аморфные бензотиофены, способы получения и способы применения
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
KR960034486A (ko) 비정상 입성장을 이용한 티탄산 바륨(BaTiO₃) 단결정 육성법
EA200300378A1 (ru) Твердые амфотерные поверхностно-активные вещества
EA200100714A1 (ru) Способ получения пантотената кальция

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU